Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
MeSH terms: Colitis; Colitis, Ulcerative; Ulcer
Intervention: PTG-100; Placebo
Intervention description: Daily dosing of PTG-100 by subject for a 12 week treatment period.; Daily dosing of Placebo capsules by subject for a 12 week treatment period.
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Enrollment: 98.0
Sex: All
Minimum age: 18 Years
Maximum age: 80 Years
Healthy volunteers: No
Keywords: ulcerative colitis; inflammatory bowel disease; PROPEL; Propel Study

Summary:

      The main objectives of this study are to evaluate the efficacy, safety, and tolerability of
      daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
    

Eligibility criteria:

        Inclusion Criteria include:

          -  Male and female subjects age 18 to 80 years, inclusive

          -  Diagnosis of UC for at least 2 months prior to screening

          -  Moderate to severe active UC as defined by Mayo Score of 6 to 12 inclusive (range of
             0-12) at baseline with endoscopy score of at least 2 (range 0-3)

          -  Subject must have had an inadequate response, loss of response to or intolerance to at
             least of of the following medications: immunomodulators, TNF-alpha antagonists or
             corticosteroids

          -  Subject is unlikely to conceive, as defined by one of the following: a) subject is
             male, b) subject is surgically sterilized female, c) subject is post-menopausal female
             >= 45 years of age with clinical documentation of menopause, or d) subject is woman of
             child bearing potential (WOCBP) and agrees to abstain from heterosexual activity, use
             adequate hormonal contraception or use double barrier contraception.

          -  For WOCBP, a negative pregnancy test at screening and within 24 hours of first dose of
             study medication

        Exclusion Criteria include:

          -  Subject has Crohn's Disease (CD), indeterminate colitis (IC) or presence or history of
             fistula with CD

          -  History of toxic megacolon, abdominal abscess, symptomatic colonic stricture or stoma;
             history or is at imminent risk of colectomy

          -  History or current evidence of colonic dysplasia or adenomatous colonic polyps

          -  Current bacterial or parasitic pathogenic enteric infection, including Clostridium
             difficile, infection with hepatitis B or C virus, infection with human
             immunodeficiency virus, infection requiring hospitalisation or intravenous
             antimicrobial therapy, or opportunistic infection within 6 months, any infection
             requiring antimicrobial therapy within 2 weeks, history of more than one episode of
             herpes zoster or any episode of disseminated zoster

          -  Live virus vaccination within one month prior to screening

          -  Subject has a concurrent clinically significant, unstable, or uncontrolled
             cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary,
             hematological, coagulation, immunological, endocrine/metabolic, or other medical
             disorder that, in the opinion of the investigator, might confound the study results or
             poses additional risk to the subject

          -  Known primary or secondary immunodeficiency

          -  History of myocardial infarction, unstable angina, transient ischaemic attack,
             decompensated heart failure requiring hospitalisation, congestive heart failure (NYHA
             Class 3 or 4), uncontrolled arrhythmias, cardiac revascularisation, stroke,
             uncontrolled hypertension, or uncontrolled diabetes within 6 months of screening

          -  Clinically meaningful laboratory abnormalities at screening

          -  Pregnant or lactating females

          -  Any surgical procedure requiring general anaesthesia within one month prior to
             screening, or planned elective surgery during the study

          -  History of malignant neoplasms or carcinoma in situ within 5 years prior to screening

          -  History of any major neurological disorders, as judged by the Investigator, or
             positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist

          -  Current or recent history of alcohol dependence or illicit drug use within 1 year
             prior to screening.

          -  Subject is mentally or legally incapacitated at the time of screening visit or has a
             history of clinically significant psychiatric disorders that would impact the
             subject's ability to participate in the trial according to the investigator

          -  Unable to attend study visits or comply with procedures

          -  Concurrent participation in any other interventional study.